Patent No. EP3186281 (titled "Combination Therapy With A Hyaluronan-Degrading Enzyme And An Immune Checkpoint Inhibitor") was filed by Halozyme on Aug 28, 2015. The application was issued on Apr 10, 2019.
This combination therapy for treating cancers, including solid tumors, comprises two compositions. The first composition contains a hyaluronidase (a hyaluronan-degrading enzyme) that is either conjugated to a polymer (e.g., PEGylated), formulated for slow/extended release (e.g., via liposomes or micelles), or encoded in a delivery vector. The second composition contains an immune checkpoint inhibitor, specifically an antibody or antigen-binding fragment targeting CTLA4, PD-1, or PD-L1. The therapy aims to decrease hyaluronan levels in tumor cells and mitigate the immunosuppressive microenvironment. The agents may be administered separately or together, systemically or via other routes, and may optionally include a corticosteroid (e.g., glucocorticoid). The hyaluronidase may be administered before, concurrently with, or sequentially to the immune checkpoint inhibitor.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description